FluoGuide receives FDA Orphan Drug Designation for FG001 in High-Grade Glioma
Copenhagen, Denmark – FluoGuide A/S, a pioneer in the cutting-edge field of precision cancer surgery, is pleased to announce its lead asset FG001 has received Orphan Drug Designation from the U. S. Food and Drug Administration as an optical imaging agent for the visualization of malignant tissue during surgery for high-grade glioma.
FluoGuide receives FDA Orphan Drug Designation for FG001 in High-Grade Glioma Read More »
